Trial Profile
Whole Brain Radiation with or without Erlotinib for Brain metastases from Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jun 2017 Status changed from recruiting to discontinued.
- 31 Jan 2012 New trial record